December 2016
-
Marinomed Biotech has announced that it signed a distribution agreement with Perrigo for its Carragelose iota-carrageenan nasal spray, and Perrigo has already launched the product in Finland, Norway, Sweden and France. The OTC nasal spray… Read more . . .
-
Armata Pharmaceuticals announced that the Cystic Fibrosis Foundation has purchased $3 million worth of the company’s common stock and that Innoviva subsidiary Innoviva Strategic Opportunities, which already held a significant number of shares in Armata,… Read more . . .
-
According to TFF Pharmaceuticals, Health Canada has issued a no objection letter regarding a Phase 1 clinical trial of TFF’s dry powder inhaled niclosamide that will evaluate 0.5, 2, and 6 mg doses in healthy volunteers… Read more . . .
-
Inhaler testing equipment company Copley Scientific is introducing a new nasal dose uniformity sampling apparatus (DUSA) interface plate designed to work with the company’s Vertus II/Plus shake and fire system for delivered dose uniformity testing… Read more . . .
-
Meissa Vaccines has announced that interim data from a Phase 1 study of its MV-014-212 intranasal recombinant live attenuated COVID-19 vaccine demonstrate that a single dose produced a good nasal IgA response with no reported… Read more . . .
-
Device company Nemera has announced the launch of a new single metered dose nasal pump called UniSpray, which is designed for delivery of systemic drugs. According to the company, UniSpray requires no priming, is compatible… Read more . . .
-
Why should inhaled drug developers consider formulating or reformulating with HFA 152a? It became very clear to us about 6 or 7 years ago that regulatory efforts to reduce global warming potential emissions in industrial… Read more . . .
-
Device developer Cambridge Healthcare Innovations (CHI) has announced the appointment of former AuroScience Head of Device Development Philip Canner as CEO. In addition to AuroScience, an Aurobindo subsidiary that develops generic inhaled drugs, Canner’s OINDP… Read more . . .
-
According to Inhalation Sciences (ISAB), a US patent covering the XposeALI in vitro cell culturing module has been extended until 2034. US Patent No. 11054414 (“Exposure system”) was originally filed in 2013, the company said. The… Read more . . .
-
Beckley Psytech said that it has initiated dosing in a Phase 1 trial of its intranasal 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT), a psychedelic compound found in the secretions of certain toads. The company is developing the intranasal formulation… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland